M. Şerban - Concepedia

Author

M. Şerban

Victor Babeș University of Medicine and Pharmacy Timișoara ORCID

Also Known As

Anna Sediva, Blanca Salazar Alvarado, D. Mihailov, M SERBAN, M Serban, M Șerban, M. SERBAN, M. Serban, M. Şerban, M.A. SERBAN

123

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Victor Babeș University of Medicine and Pharmacy Timișoara Novo Nordisk (Denmark)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Clinical Emergency Hospital Bucharest Camera de Comerț Industrie și Agricultură Timișoara

MŞ

About

M. Şerban is an author at Victor Babeș University of Medicine and Pharmacy Timișoara specializing in medicine, immunology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	535
2	Health Sciences	3	3	366
3	Public Health	2	2	93
4	Allergy	2	2	77
5	Cellular Therapies	1	1	17

M. Şerban

Publications

991

Citations

H-Index

Page 1

	Year	Citations
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors Barbara A. Konkle, Liselotte S. Ebbesen, Elisabeth Erhardtsen, Journal of Thrombosis and Haemostasis ThrombosisSecondary ProphylaxisHematologyClinical TrialsRecombinant Factor Viia	2007	325
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors Cindy Leissinger, A. Gringeri, Bülent Antmen, New England Journal of Medicine	2011	219
Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: A cohort study Beáta Tóth, Alexander Mihas, Ewa Bernatowska, Molecular Immunology ImmunohematologyX-linked AgammaglobulinemiaAutoimmune DiseaseCentral EuropeGenetic Epidemiology	2009	67
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity Johnny Mahlangu, Karin Weldingh, Steven R. Lentz, Journal of Thrombosis and Haemostasis Clinical ImmunologyMolecular ImmunologyImmunogeneticsVatreptacog AlfaAllergy	2015	59
Haemophilia Care in Europe: the ESCHQoL study W. Schramm, A. Gringeri, Rolf Ljung, Haemophilia	2012	54
Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency Michael Borte, M. Şerban, Teresa Gonzalez‐Quevedo, Journal of Clinical Immunology	2011	49
Efficacy and safety of a <scp>VWF</scp>/<scp>FVIII</scp> concentrate (wilate<sup>®</sup>) in inherited von Willebrand disease patients undergoing surgical procedures Alok Srivastava, M. Şerban, Sylvia Werner, Haemophilia	2016	37
Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glyco<scp>PEG</scp>ylated factor <scp>IX</scp> Miguel A. Escobar, Ramin Tehranchi, Faraizah Abdul Karim, Haemophilia	2016	34
Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels Adela Chiriţă-Emandi, Nicoleta Andreescu, Cristian G. Zimbru, Scientific Reports Family MembersGeneticsGenetic EpidemiologyPathologyDisease Gene Identification	2020	26
Functional limitations in <scp>R</scp>omanian children with haemophilia: further testing of psychometric properties of the <scp>P</scp>aediatric <scp>H</scp>aemophilia <scp>A</scp>ctivities <scp>L</scp>ist Wim G Groen, Janjaap van der Net, Adrian Lăcătuşu, Haemophilia Quality Of LifeFurther TestingPediatric RehabilitationChild Mental HealthPsychometric Properties	2013	23

Page 1